System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Alona Zer

Oncology — Rambam Health Care Campus, Israel

LeadR Profile

Alona Zer Rambam Health Care Campus Israel
1 119 ScienceLeadR Reputation 1119

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Hematology - Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2010 - 2026
Source: PubMed

Tel Aviv University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 227

Citations

Citations: 14 851 1st author: 34 Last author: 27 Unique author: 0

Main journals

J Thorac Oncol 50
J Clin Oncol 42
Ann Oncol 34
Cancer Res 6
Lung Cancer 6

Best Journals

Ann Oncol 27
J Clin Oncol 23
N Engl J Med 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort.
radiotherapy, cells, lung, neoplasms, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics		Front Oncol20260
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
research design, neoplasms, carcinoma, non-small-cell lung, uncertainty, therapeutics, rna		J Thorac Oncol20260
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.
safety, neoplasms, carcinoma, non-small-cell lung, therapeutics		JTO Clin Res Rep20262
Novel germline genetic variants associated with venous thrombo-embolism (VTE) and arterial thrombo-embolism (ATE) risk in patients with ALK and ROS1 fusion non-small cell lung cancer (NSCLC).
cells, lung, embolism, hemorrhage, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, thrombosis, hemostasis		Thromb Res20260
LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli health maintenance organization (HMO).
cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, maintenance, lung neoplasms, small cell lung carcinoma, therapeutics, health maintenance organizations		Expert Rev Anticancer Ther20260

Clinical Studies 14

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 3 7
Phase 2 4
N/A 2
Phase 1 1

By status:

Active not recruiting 6
Completed 3
Recruiting 3
Unknown 2

By type:

Interventional 12
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 0
multicentricup10 10

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C mutant Non Small Cell Lung Cancer
NCT06890598 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma, carcinoma		Phase 3Recruiting2025
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR) Mutated Advanced or Metastatic Non small Cell Lung Cancer
NCT05388669 — injections, cells, epidermal growth factor, lung, growth, neoplasms, carcinoma, non-small-cell lung, tablets, drug therapy, lung neoplasms, receptors, growth factor, small cell lung carcinoma, hyaluronoglucosaminidase, chemotherapy, carcinoma		Phase 3Active not recruiting2022
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891 — registries, cells, neoplasms, carcinoma, non-small-cell lung, therapeutics		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS